Synthesis and in vitro transdermal penetration enhancing activity of lactam N-acetic acid esters

Journal of Pharmaceutical Sciences

Volumn 85, Issue 2, 1996, Pages 150-154

  Michniak, Bozena B ^a,b   Player, Mark R ^a,b   Sowell Sr , J Walter ^a,b  

^a UNIVERSITY OF SOUTH CAROLINA   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 OXOPIPERIDINE 1 ACETIC ACID DECYL ESTER; 2 OXOPYRROLIDINE 1 ACETIC ACID DODECYL ESTER; 2 PYRROLIDONE DERIVATIVE; ACETIC ACID ESTER; FLUOROURACIL; HYDROCORTISONE; HYDROCORTISONE ACETATE; LACTAM; LAUROCAPRAM; METHOTREXATE; PIPERIDONE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BIODEGRADATION; CELL MEMBRANE PERMEABILITY; CONTROLLED STUDY; DRUG DIFFUSION; DRUG PENETRATION; DRUG SYNTHESIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PSORIASIS; SKIN PENETRATION; STRATUM CORNEUM;

EID: 0030026225     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1021/js950331n     Document Type: Article

References (58)

1. Cleary, G. W. In Topical Drug Bioavailability, Bioequivalence, and Penetration. Shah, V. P.; Maibach, H. I., Eds., Plenum: New York, 1993; pp 17-68.
2. Waranis, P.; Sloan, K. B. J. Pharm. Sci. 1987, 76, 587-595.
3. Van Osman, Huff, B.; Liversidge, G. G.; McIntyre, G. L. Pharm. Res. 1995, 12, 751-755.
4. Brucks, R.; Nanavaty, M.; Jung, D.; Siegel, F. Pharm. Res. 1989, 6, 679-701.
5. Walters, K. A.; Hadgraft, J. (Eds.) Pharmaceutical Skin Penetration Enhancement; Marcel Dekker: New York, 1993.
6. Katz, M.; Poulsen, B. J. In Handbook of Experimental Pharmacology; Brodie, B. B.; Gillette, J., Eds.; Springer-Verlag: New York, 1971; pp 103.
7. Sasaki, H.; Kojima, M.; Mori, Y.; Nakamura, J.; Shibasaki, J. Int. J. Pharm. 1990, 60, 177-183.
8. Williams, A. C.; Barry, B. W. Int. J. Pharm. 1989, 36, 43-50.
9. French, E. J.; Pouton, C. W.; Walters, K. A. In Pharmaceutical Skin Penetration Enhancement; Walters, K. A.; Hadgraft, J., Eds.; Marcel Dekker: New York, 1993; pp 113-143.
10. Baker, H. J. Invest. Dermatol. 1968, 50, 283-288.
11. Vaidyanathan, R.; Rajadhaksha, V. J.; Kim, B. K.; Anisko, J. J. In Transdermal Delivery of Drugs; Kydonieus, A. F.; Berner, B., Eds., CRC: Boca Raton, FL, 1987; Vol. II, pp 63-83.
12. Michniak, B. B.; Player, M. R.; Godwin, D. A.; Phillips, C. A.; Sowell, J. W. Int. J. Pharm. 1995, 116, 201-209.
13. Michniak, B. B.; Player, M. R.; Fuhrman, L. C.; Christensen, C. A.; Chapman, J. M.; Sowell, J. W. Int. J. Pharm. 1994, 110, 231-239.
14. Michniak, B. B.; Player, M. R.; Chapman, J. M.; Sowell, J. W. J. Controlled Release 1994, 32, 147-154.
15. Hirvonen, J.; Rytting, J. H.; Paronen, P.; Urtti, A. Pharm. Res. 1991, 8, 933-937.
16. Quan, D.; Higuchi, R. I.; Takayama, D.; Higashiyama, K.; Nagai, T. Drug Des. Delivery 1990, 6, 61-71.
17. Okamoto, H,; Hashida, M.; Sezaki, H. J. Pharm. Sci. 1988, 77, 418-424.
18. Mirejovsky, D.; Takruri, H. J. Pharm. Sci. 1986, 75, 1089-1093.
19. Barry, B. W. J. Controlled Release 1991, 15, 237-248.
20. Sugibayashi, K.; Nakayama, S.; Seki, T.; Hosoya, K.-I.; Morimoto, Y. J. Pharm. Sci. 1992, 81, 58-64.
21. Phillips, C. A.; Michniak, B. B. J. Pharm. Sci. 1995, 84, 1427-1433.
22. Marty, J. P.; Dervault, A. M.; Chanez, J. F.; Doucet, O.; Samour, C. M. Proceedings of the 16th International Symposium on Controlled Release of Bioactive Materials; Controlled Release Society; Lincolnshire, IL, 1989; pp 179.
23. Wong, O.; Huntington, J.; Konishi, R.; Rytting, J. H.; Higuchi, T. J. Pharm. Sci. 1988, 77, 967-971.
24. Michniak, B. B.; Player, M. R.; Fuhrman, L. C.; Christensen, C. A.; Chapman, J. M.; Sowell, J. W. Int. J. Pharm. 1993, 94, 203-210.
25. Michniak, B. B.; Player, M. R.; Chapman, J. M.; Sowell, J. W. Int. J. Pharm. 1993, 91, 85-93.
26. Bromoacetyl bromide and the intermediate alkyl bromoacetate are lachrymators, sensitizers, and alkylating agents. NaH is highly caustic and pyrophoric. This procedure should only be carried out by a qualified technician wearing appropriate safety clothing, and skin and eye protection, who is using a properly functioning fume hood.
27. Sloan, K. B.; Beall, H. D.; Weimar, W. R.; Villaneuva, R. Int. J. Pharm. 1991, 73, 97-104.
28. Windholtz, M. The Merck Index, 10th ed.; Merck: Rahway, NJ, 1983; pp 693.
29. Chien, Y. W. Novel Drug Delivery Systems: Fundamentals, Developmental Concepts, Biomedical Assessments; Marcel Dekker: New York, 1982; pp 551-553.
30. Loftsson, T.; Gildersleeve, N.; Soliman, R.; Bodor, N. Acta Pharm. Nord. 1989, 1, 17-22.
31. Michniak, B. B.; Chapman, J. M.; Seyda, K. L. J. Pharm. Sci. 1993, 82, 214-219.
32. Tauber, U.; Rost, K. I. In Pharmacology and the Skin; Schroot, B.; Schaefer, H. Eds.; Karger: Basel, 1987; pp 170-183.
33. Barry, B. W.; Bennett, S. L. J. Pharm. Pharmacol. 1987, 39, 533-546.
34. Godwin, D. A.; Michniak, B. B. Pharm. Res. 1995, 12 (Suppl), S269.
35. Buyuktimkin, S.; Buyuktimkin, N.; Rytting, J. H. Pharm. Res. 1993, 10, 1632-1637.
36. Francoeur, M. L.; Golden, G. M.; Potts, R. O. Pharm. Res. 1990, 7, 621-627.
37. Knutson, K.; Potts, R. O.; Guzek, D. B.; Golden, G. M.; McKie, J. E.; Lambert, W.J.; Higuchi, W. I. J. Controlled Release 1985, 2, 67-87.
38. Kai, T.; Mak, V. W.; Potts, R. O.; Guy, R. H. J. Controlled Release 1990, 12, 103-112.
39. Takeuchi, Y.; Yasukawa, H.; Yanaoka, Y.; Kato, Y.; Morimoto, Y.; Fukumori, Y.; Fukuda, T. Chem. Pharm. Bull. 1992, 40, 1887-1892.
40. Barry, B. W. Int. J. Cosmet. Sci. 1988, 10, 281-293.
41. Barry, B. W. In In Vitro Percutaneous Absorption Principles, Fundamentals and Applications; Bronough, R. L.; Maibach, H. I., Eds., CRC: Boca Raton, FL, 1991; pp 165-185.
42. Bouwstra, J. A.; Peschier, L. J. C.; Brussee, J.; Bodde, H. E. Int. J. Pharm. 1989, 52, 47-54.
43. Kim, Y.; Higuchi, W. I.; Herron, J. N.; Abraham, W. Biochim. Biophys. Acta 1993, 1148, 139-151.
44. Higuchi, W. I.; Yoneto, K.; Jiskoot, W.; Herron, J. N.; Pharm. Res. 1993, 10, S246.
45. Goodman, M.; Barry, B. W. J. Pharm. Pharmacol. 1986, 38 (Suppl), 71P.
46. Bouwstra, J. A.; Bodde, H. E. In Percutaneous Penetration Enhancers, Smith, L. W.; Maibach, H. I., Eds., CRC: Boca Raton, FL, 1995; pp 137-157.
47. Hadgraft, J.; Williams, D. G.; Allan, G. In Pharmaceutical Skin Penetration Enhancement; Walters, K. A.; Hadgraft, J., Eds., Marcel Dekker: New York, 1993; pp 175-197.
48. Schukler, F.; Lee, G. Int. J. Pharm. 1992, 80, 81-89.
49. Schukler, F.; Lee, G. Int. J. Pharm. 1991, 70, 173-186.
50. Lewis, D.; Hadgraft, J. Int. J. Pharm. 1990, 65, 211-218.
51. Schuckler, F.; Bouwstra, J. A.; Gooris, G. S.; Lee, G. J. Controlled Release 1993, 23, 27-31.
52. Engblom, J.; Engstrom, S. Int. J. Pharm. 1993, 98, 173-177.
53. Aungst, B. J.; Rogers, N. J.; Shefter, E. Int. J. Pharm. 1986, 33, 225-234.
54. Sasaki, H.; Kojima, M.; Mori, Y.; Nakamura, J.; Shibasaki, J. J. Pharm. Sci. 1991, 80, 533-538.
55. Brain, K. R.; Walters, K. A. In Pharmaceutical Skin Penetration Enhancement; Walters, K. A.; Hadgraft, J., Eds., Marcel Dekker: New York, 1993; pp 389-416.
56. Hoogstraate, A. J.; Verhoef, J.; Brussee, J.; IJzerman, A. P.; Spies, F.; Bodde, H. Int. J. Pharm. 1991, 76, 37-47.
57. Lewis, D; Hadgraft, J. Int. J. Pharm. 1990, 65, 211-218.
58. Williams, D. Ph.D. Thesis, University of Wales, England, 1991.